NEW PATENTS ISSUED IN U.S. AND EUROPE FOR TECHNOLOGY USED IN CORGENIX NEXT GENERATION PREDICTIVE CARDIOVASCULAR DIAGNOSTIC PRODUCT LINE
US Patent # 7,455,976 was issued
European patent # EP 1 548-436 B1 was issued
The latest patents add to previous US patents (# 5,900,359 issued
In all countries where the use of products employing this technology has not been cleared, the products shall not be used for diagnostic use as the performance characteristics have not been established.
About AtherOx(R)
The AtherOx technology utilizes oxidized low-density lipoprotein (oxLDL) complexed with the plasma protein B2GPI. Although oxLDL has been implicated in cardiovascular disease, according to results published in the Annals of N.Y. Academy of Science (2007), determination of oxLDL/B2GPI complexes, rather than oxLDL alone, may be a more physiologic and accurate way of assessing the risk of progressive atherosclerotic cardiovascular disease in individuals with systemic lupus erythematosus and lupus-like disorders. Corgenix licensed this technology in 2002, and is developing additional products utilizing this unique platform. In addition to the four U.S. patents which have been issued, several others are pending.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for vascular diseases, immunology disorders, and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 52 diagnostic products through a global distribution network. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.
SOURCE Corgenix Medical Corporation